Suzanne Duell
Older Australians will soon have access to the first respiratory syncytial virus (RSV) vaccine funded under the National Immunisation Program (NIP), with GSK’s AREXVY available from 15 May 2026.
More than two million Australians aged 75 and over, and Aboriginal and Torres Strait Islander people aged 60 and over, will be eligible to receive the vaccine through their GP or pharmacist. AREXVY helps protect against lower respiratory tract disease caused by RSV, a contagious virus that can lead to serious illness in older adults.
Catherine Hughes, Executive Director of Immunisation Foundation Australia, said the inclusion of AREXVY on the NIP highlights that immunisation is a lifelong strategy. “It will help protect older adults from serious respiratory illness, prevent avoidable hospital admissions and ease pressure on the health system during peak respiratory seasons,” she said.
RSV is a common respiratory virus that spreads through droplets and contaminated surfaces. While symptoms often resemble a cold, the virus can cause pneumonia, respiratory failure and, in rare cases, death. Older adults and those with chronic conditions such as COPD, asthma or heart disease are at higher risk of severe illness.
National Seniors Australia CEO Chris Grice said the funding recognises the importance of protecting older Australians. “Many older people care for grandchildren, increasing their exposure to RSV. This funding supports them to make informed decisions about their health,” he said.
Lung Foundation Australia CEO Mark Brooke said the vaccine offers an important opportunity for prevention. “Funded access to an RSV vaccine gives older people at highest risk the chance to avoid serious illness and maintain their quality of life,” he said.
For Adelaide resident Suzanne Duell, 78, the impact of RSV was severe. An active volunteer in her community, she became unwell after experiencing breathlessness and a persistent cough that left her exhausted. After three visits to her GP, a nasal swab confirmed RSV. She described the illness as “much worse than COVID.” Her recovery was prolonged and has made her more cautious about respiratory illness, particularly as she lives alone. Suzanne has since returned to volunteering and staying active in her community.
Professor Charlotte Hespe AM from the University of Sydney said the move acknowledges RSV as a significant health threat. “AREXVY can be given at the same time as the flu jab, making appointments more efficient,” she said.
GSK Australia’s Executive Country Medical Director, Dr Alan Paul, said the inclusion of AREXVY on the NIP demonstrates a strong commitment to protecting older Australians. “This decision recognises the significant health burden RSV can place on older adults and Aboriginal and Torres Strait Islander people,” he said.
AREXVY was approved by the Therapeutic Goods Administration in 2024 following international clinical trials involving nearly 25,000 older adults. It remains available for adults aged over 60, and for those aged 50–59 at increased risk, though these groups are not currently funded under the NIP.